latest news releases from the newsroom
STEC Board Approves $10 Million Stock Repurchase Program
SANTA ANA, Calif., Nov. 17, 2008 (GLOBE NEWSWIRE) -- STEC, Inc. (Nasdaq:STEC) today announced, that its board of directors has authorized the Company to repurchase up to $10 million of its common stock over an 18-month period commencing November 19, 2008 following the expiration of its existing stock repurchase plan on November 18, 2008.
Artificial Life, Inc.
Artificial Life's MoPA-TV is Nominated in the GSMA's Asia Mobile Awards 2008
LOS ANGELES and HONG KONG, Nov. 17, 2008 (GLOBE NEWSWIRE) -- Artificial Life, Inc. (OTCBB:ALIF) (www.artificial-life.com), a leading full service provider of award-winning mobile technology, games and applications, today announces that MoPA-TV(tm), the company's innovative cross platform technology, has been nominated in the GSMA's Asia Mobile Awards 2008 under the category of Best Mobile Music, TV or Video Service.
SunOpta Appoints Deloitte & Touche LLP as Independent Registered Public Accountants for Company
TORONTO, Nov. 17, 2008 (GLOBE NEWSWIRE) -- SunOpta Inc. (Nasdaq:STKL) (TSX:SOY) today announced that the Company's Audit Committee have appointed Deloitte & Touche LLP ("D&T") to serve as the Company's independent registered public accounting firm. This decision was taken after a careful and thoughtful assessment of three engagement proposals received from independent registered international public accounting firms including the Company's former auditors.
Retalix Announces Third Quarter 2008 Results
RA'ANANA, Israel, Nov. 17, 2008 (GLOBE NEWSWIRE) -- Retalix(r) Ltd. (Nasdaq:RTLX) today announced the results for the third quarter and nine month period ended September 30, 2008. The Company also announced that due to the current economic and financial environment, it is revising its outlook for FY 2008.
Achillion Pharmaceuticals, Inc.
Achillion to Present At Lazard Capital Markets 5th Annual Healthcare Conference
NEW HAVEN, Conn., Nov. 17, 2008 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a corporate overview and update on the Company's programs in HCV and serious bacterial infections at the Lazard Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18, 2008 at 1:40 p.m. at the St. Regis Hotel in New York City.